ArticleInternational journal of molecular medicine2026
Cepharanthine inhibits tick‑borne encephalitis virus infection through modulation of the stress and inflammation response.
Article in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cepharanthine is a potential candidate for developing antiviral agents against tick‑borne encephalitis virus (TBEV), which is a major cause of arboviral neuroinvasive diseases in humans. Cepharanthine is the only bisbenzylisoquinoline alkaloid for treating human diseases due to its unique pharmacological properties. Management of endoplasmic reticulum stress and inflammation response is implicated in therapeutic strategies for TBEV infection. The present study aimed to explore the antiviral efficacy and underlying mechanisms of cepharanthine against TBEV in human lung adenocarcinoma A549 cells and neuroblastoma SH‑SY5Y cells. In co‑treatment and pre‑treatment schemes, cepharanthine exhibited a potent inhibitory effect on TBEV propagation. The antiviral effect of cepharanthine was evidenced by a reduction in TBEV RNA replication, viral protein expression and infectious virus release. The levels of inflammatory cytokines, including tumor necrosis factor‑α, interleukin (IL‑) 1β and IL‑11, induced by TBEV infection were markedly decreased in A549 cells treated with cepharanthine. The induction of IL‑11 was impaired in infected SH‑SY5Y cells treated with cepharanthine. TBEV infection upregulated the expression of C/EBP homologous protein, which was downregulated by cepharanthine treatment. Phosphorylation of eukaryotic initiation factor 2α was enhanced upon cepharanthine treatment during TBEV infection. These
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.